158 related articles for article (PubMed ID: 25682003)
1. Growth and migration of LNCaP prostate cancer cells are promoted by triclosan and benzophenone-1 via an androgen receptor signaling pathway.
Kim SH; Hwang KA; Shim SM; Choi KC
Environ Toxicol Pharmacol; 2015 Mar; 39(2):568-76. PubMed ID: 25682003
[TBL] [Abstract][Full Text] [Related]
2. Influence of hexabromocyclododecane and 4-nonylphenol on the regulation of cell growth, apoptosis and migration in prostatic cancer cells.
Kim SH; Nam KH; Hwang KA; Choi KC
Toxicol In Vitro; 2016 Apr; 32():240-7. PubMed ID: 26804032
[TBL] [Abstract][Full Text] [Related]
3. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
4. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ
Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223
[TBL] [Abstract][Full Text] [Related]
6. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
Yan J; Xie B; Capodice JL; Katz AE
Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor inhibits epithelial-mesenchymal transition, migration, and invasion of PC-3 prostate cancer cells.
Huo C; Kao YH; Chuu CP
Cancer Lett; 2015 Dec; 369(1):103-11. PubMed ID: 26297988
[TBL] [Abstract][Full Text] [Related]
8. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
9. Galbanic acid decreases androgen receptor abundance and signaling and induces G1 arrest in prostate cancer cells.
Zhang Y; Kim KH; Zhang W; Guo Y; Kim SH; Lü J
Int J Cancer; 2012 Jan; 130(1):200-12. PubMed ID: 21328348
[TBL] [Abstract][Full Text] [Related]
10. Androgens regulate Hedgehog signalling and proliferation in androgen-dependent prostate cells.
Sirab N; Terry S; Giton F; Caradec J; Chimingqi M; Moutereau S; Vacherot F; de la Taille A; Kouyoumdjian JC; Loric S
Int J Cancer; 2012 Sep; 131(6):1297-306. PubMed ID: 22131072
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor-mediated repression of novel target genes.
Prescott J; Jariwala U; Jia L; Cogan JP; Barski A; Pregizer S; Shen HC; Arasheben A; Neilson JJ; Frenkel B; Coetzee GA
Prostate; 2007 Sep; 67(13):1371-83. PubMed ID: 17624924
[TBL] [Abstract][Full Text] [Related]
12. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase.
Bai VU; Cifuentes E; Menon M; Barrack ER; Reddy GP
J Cell Physiol; 2005 Aug; 204(2):381-7. PubMed ID: 15887248
[TBL] [Abstract][Full Text] [Related]
14. Methoxychlor and triclosan stimulates ovarian cancer growth by regulating cell cycle- and apoptosis-related genes via an estrogen receptor-dependent pathway.
Kim JY; Yi BR; Go RE; Hwang KA; Nam KH; Choi KC
Environ Toxicol Pharmacol; 2014 May; 37(3):1264-74. PubMed ID: 24835555
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
16. Preferential induction of G1 arrest in androgen-responsive human prostate cancer cells by androgen receptor signaling antagonists DL3 and antiandrogen bicalutamide.
Lu S; Tan Z; Wortman M; Lu S; Dong Z
Cancer Lett; 2010 Dec; 298(2):250-7. PubMed ID: 20675041
[TBL] [Abstract][Full Text] [Related]
17. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
Hobisch A; Fritzer A; Comuzzi B; Fiechtl M; Malinowska K; Steiner H; Bartsch G; Culig Z
Prostate; 2006 Mar; 66(4):413-20. PubMed ID: 16302272
[TBL] [Abstract][Full Text] [Related]
18. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
19. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
Mulholland DJ; Read JT; Rennie PS; Cox ME; Nelson CC
Oncogene; 2003 Aug; 22(36):5602-13. PubMed ID: 12944908
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor functions as a negative transcriptional regulator of DEPTOR, mTOR inhibitor.
Kanno Y; Zhao S; Yamashita N; Yanai K; Nemoto K; Inouye Y
J Toxicol Sci; 2015 Dec; 40(6):753-8. PubMed ID: 26558456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
